Debevoise Advises SVB Leerink as Co-Financial Advisor to LHC Group in Its Sale to Optum for Approximately $5.4 Billion

30 March 2022

Debevoise & Plimpton LLP is advising SVB Leerink as co-financial advisor to LHC Group (NASDAQ: LHCG) in its sale to UnitedHealth Group’s Optum unit for approximately $5.4 billion. Under the terms of the transaction, Optum will pick up LHC Group Inc. for $170 per share. For more information, please see the company’s press release.

SVB Leerink is an investment bank specializing in healthcare and technology. LHC Group, Inc. is a national provider of in-home healthcare services and innovations. Optum is an information and technology-enabled health services business.

The Debevoise team is led by M&A partner Andrew Bab and Includes associate Tiancheng (TC) Huang.